Global Point of Care Molecular Diagnosis Market

Point of Care Molecular Diagnosis Comprehensive Study by End Use (Physician Offices, Health Department Clinics, Pharmacy Clinics, Others), Product (Assays & Kits, Instruments/Analysers, Services & Software), Tests (RT-PCR, INAAT, Others) Players and Region - Global Market Outlook to 2030

Point of Care Molecular Diagnosis Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 8.77%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Point of Care Molecular Diagnosis
Point of Care Molecular allows a physician to make a diagnosis or rule out a diagnosis and treat a patient while they are still in the clinic. Furthermore, as compared to rapid antigen detection tests, molecular assays have shown better sensitivity, removing the need for secondary confirmation of negative results and leading to much more appropriate antibiotic administration, including the avoidance of antibiotic use for viral infections.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR8.77%


The demand for POC Molecular Diagnostics is increasing with each passing day. The businesses in this industry facing major competition on a global scale with leading players of the market who hold a major market share. The Leading Players are engaged in organic and non-organic strategic global expansion to maintain their Market Position. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Point of Care Molecular Diagnosis market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Roche (Switzerland), Abbott Laboratories (United States), Biomerieux (France), Danaher (United States), Roche diagnostics (Switzerland), Meridian biosciences (United States), Quidel (United States), Sanofi (France), Merck (United States) and Johnson and Johnson (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Cardea (United States), Inflammatix (United States) and Sherlock Biosciences (United States).

Segmentation Overview
AMA Research has segmented the market of Global Point of Care Molecular Diagnosis market by and Region.



On the basis of geography, the market of Point of Care Molecular Diagnosis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Use, the sub-segment i.e. Physician Offices will boost the Point of Care Molecular Diagnosis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Product, the sub-segment i.e. Assays & Kits will boost the Point of Care Molecular Diagnosis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Tests, the sub-segment i.e. RT-PCR will boost the Point of Care Molecular Diagnosis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
The Rise in CLIA-Waived Molecular POC Tests

Market Growth Drivers:
Microfluidics and Other Instrumentation Technologies That Allow for the Creation of Low-Cost Platforms and Tests

Challenges:
Direct Interaction With a Patient During Specimen Collection Poses the Highest Danger

Restraints:
Time-Consuming and Stringent Government Regulations and Policies

Opportunities:
In Resource-Constrained Environments, Molecular POCT is Becoming Increasingly Beneficial

Market Leaders and their expansionary development strategies
In March 2021 Roche Released a Statement Stating the Acquisition of Genmark. The ePlex technology from GenMark provides clinicians with quick and actionable findings, allowing them to pinpoint the source of infection and the most effective therapy, potentially saving lives and reducing healthcare costs. Roche's diagnostic portfolio has been enhanced by the integration of GenMark's unique multiplex technology, which addresses a wide range of infectious disease testing needs, including respiratory and bloodstream infections.
In 2020, bioMérieux SA has partnered with the African Medical Supplies Platform (AMSP) to provide African Union member states with high-quality COVID-19 diagnostic solutions from the bioMérieux Pandemic Response Portfolio. and In 2020, Abbott Laboratories introduces the ID NOW PoC test system.


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Government Regulatory and Research Organizations, Healthcare Organization, Pharmaceutical Companies and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By End Use
  • Physician Offices
  • Health Department Clinics
  • Pharmacy Clinics
  • Others

By Product
  • Assays & Kits
  • Instruments/Analysers
  • Services & Software

By Tests
  • RT-PCR
  • INAAT
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Microfluidics and Other Instrumentation Technologies That Allow for the Creation of Low-Cost Platforms and Tests
    • 3.3. Market Challenges
      • 3.3.1. Direct Interaction With a Patient During Specimen Collection Poses the Highest Danger
    • 3.4. Market Trends
      • 3.4.1. The Rise in CLIA-Waived Molecular POC Tests
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Point of Care Molecular Diagnosis, by End Use, Product, Tests and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Point of Care Molecular Diagnosis (Value)
      • 5.2.1. Global Point of Care Molecular Diagnosis by: End Use (Value)
        • 5.2.1.1. Physician Offices
        • 5.2.1.2. Health Department Clinics
        • 5.2.1.3. Pharmacy Clinics
        • 5.2.1.4. Others
      • 5.2.2. Global Point of Care Molecular Diagnosis by: Product (Value)
        • 5.2.2.1. Assays & Kits
        • 5.2.2.2. Instruments/Analysers
        • 5.2.2.3. Services & Software
      • 5.2.3. Global Point of Care Molecular Diagnosis by: Tests (Value)
        • 5.2.3.1. RT-PCR
        • 5.2.3.2. INAAT
        • 5.2.3.3. Others
      • 5.2.4. Global Point of Care Molecular Diagnosis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Point of Care Molecular Diagnosis (Price)
  • 6. Point of Care Molecular Diagnosis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biomerieux (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Danaher (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Roche diagnostics (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Meridian biosciences (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Quidel (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson and Johnson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Point of Care Molecular Diagnosis Sale, by End Use, Product, Tests and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Point of Care Molecular Diagnosis (Value)
      • 7.2.1. Global Point of Care Molecular Diagnosis by: End Use (Value)
        • 7.2.1.1. Physician Offices
        • 7.2.1.2. Health Department Clinics
        • 7.2.1.3. Pharmacy Clinics
        • 7.2.1.4. Others
      • 7.2.2. Global Point of Care Molecular Diagnosis by: Product (Value)
        • 7.2.2.1. Assays & Kits
        • 7.2.2.2. Instruments/Analysers
        • 7.2.2.3. Services & Software
      • 7.2.3. Global Point of Care Molecular Diagnosis by: Tests (Value)
        • 7.2.3.1. RT-PCR
        • 7.2.3.2. INAAT
        • 7.2.3.3. Others
      • 7.2.4. Global Point of Care Molecular Diagnosis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Point of Care Molecular Diagnosis (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Point of Care Molecular Diagnosis: by End Use(USD Million)
  • Table 2. Point of Care Molecular Diagnosis Physician Offices , by Region USD Million (2018-2023)
  • Table 3. Point of Care Molecular Diagnosis Health Department Clinics , by Region USD Million (2018-2023)
  • Table 4. Point of Care Molecular Diagnosis Pharmacy Clinics , by Region USD Million (2018-2023)
  • Table 5. Point of Care Molecular Diagnosis Others , by Region USD Million (2018-2023)
  • Table 6. Point of Care Molecular Diagnosis: by Product(USD Million)
  • Table 7. Point of Care Molecular Diagnosis Assays & Kits , by Region USD Million (2018-2023)
  • Table 8. Point of Care Molecular Diagnosis Instruments/Analysers , by Region USD Million (2018-2023)
  • Table 9. Point of Care Molecular Diagnosis Services & Software , by Region USD Million (2018-2023)
  • Table 10. Point of Care Molecular Diagnosis: by Tests(USD Million)
  • Table 11. Point of Care Molecular Diagnosis RT-PCR , by Region USD Million (2018-2023)
  • Table 12. Point of Care Molecular Diagnosis INAAT , by Region USD Million (2018-2023)
  • Table 13. Point of Care Molecular Diagnosis Others , by Region USD Million (2018-2023)
  • Table 14. South America Point of Care Molecular Diagnosis, by Country USD Million (2018-2023)
  • Table 15. South America Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 16. South America Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 17. South America Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 18. Brazil Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 19. Brazil Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 20. Brazil Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 21. Argentina Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 22. Argentina Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 23. Argentina Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 24. Rest of South America Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 25. Rest of South America Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 26. Rest of South America Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 27. Asia Pacific Point of Care Molecular Diagnosis, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 29. Asia Pacific Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 30. Asia Pacific Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 31. China Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 32. China Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 33. China Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 34. Japan Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 35. Japan Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 36. Japan Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 37. India Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 38. India Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 39. India Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 40. South Korea Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 41. South Korea Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 42. South Korea Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 43. Taiwan Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 44. Taiwan Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 45. Taiwan Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 46. Australia Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 47. Australia Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 48. Australia Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 52. Europe Point of Care Molecular Diagnosis, by Country USD Million (2018-2023)
  • Table 53. Europe Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 54. Europe Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 55. Europe Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 56. Germany Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 57. Germany Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 58. Germany Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 59. France Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 60. France Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 61. France Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 62. Italy Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 63. Italy Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 64. Italy Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 65. United Kingdom Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 66. United Kingdom Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 67. United Kingdom Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 68. Netherlands Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 69. Netherlands Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 70. Netherlands Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 71. Rest of Europe Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 72. Rest of Europe Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 73. Rest of Europe Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 74. MEA Point of Care Molecular Diagnosis, by Country USD Million (2018-2023)
  • Table 75. MEA Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 76. MEA Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 77. MEA Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 78. Middle East Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 79. Middle East Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 80. Middle East Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 81. Africa Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 82. Africa Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 83. Africa Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 84. North America Point of Care Molecular Diagnosis, by Country USD Million (2018-2023)
  • Table 85. North America Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 86. North America Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 87. North America Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 88. United States Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 89. United States Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 90. United States Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 91. Canada Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 92. Canada Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 93. Canada Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 94. Mexico Point of Care Molecular Diagnosis, by End Use USD Million (2018-2023)
  • Table 95. Mexico Point of Care Molecular Diagnosis, by Product USD Million (2018-2023)
  • Table 96. Mexico Point of Care Molecular Diagnosis, by Tests USD Million (2018-2023)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Point of Care Molecular Diagnosis: by End Use(USD Million)
  • Table 108. Point of Care Molecular Diagnosis Physician Offices , by Region USD Million (2025-2030)
  • Table 109. Point of Care Molecular Diagnosis Health Department Clinics , by Region USD Million (2025-2030)
  • Table 110. Point of Care Molecular Diagnosis Pharmacy Clinics , by Region USD Million (2025-2030)
  • Table 111. Point of Care Molecular Diagnosis Others , by Region USD Million (2025-2030)
  • Table 112. Point of Care Molecular Diagnosis: by Product(USD Million)
  • Table 113. Point of Care Molecular Diagnosis Assays & Kits , by Region USD Million (2025-2030)
  • Table 114. Point of Care Molecular Diagnosis Instruments/Analysers , by Region USD Million (2025-2030)
  • Table 115. Point of Care Molecular Diagnosis Services & Software , by Region USD Million (2025-2030)
  • Table 116. Point of Care Molecular Diagnosis: by Tests(USD Million)
  • Table 117. Point of Care Molecular Diagnosis RT-PCR , by Region USD Million (2025-2030)
  • Table 118. Point of Care Molecular Diagnosis INAAT , by Region USD Million (2025-2030)
  • Table 119. Point of Care Molecular Diagnosis Others , by Region USD Million (2025-2030)
  • Table 120. South America Point of Care Molecular Diagnosis, by Country USD Million (2025-2030)
  • Table 121. South America Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 122. South America Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 123. South America Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 124. Brazil Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 125. Brazil Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 126. Brazil Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 127. Argentina Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 128. Argentina Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 129. Argentina Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 130. Rest of South America Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 131. Rest of South America Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 132. Rest of South America Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 133. Asia Pacific Point of Care Molecular Diagnosis, by Country USD Million (2025-2030)
  • Table 134. Asia Pacific Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 135. Asia Pacific Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 136. Asia Pacific Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 137. China Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 138. China Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 139. China Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 140. Japan Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 141. Japan Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 142. Japan Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 143. India Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 144. India Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 145. India Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 146. South Korea Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 147. South Korea Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 148. South Korea Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 149. Taiwan Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 150. Taiwan Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 151. Taiwan Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 152. Australia Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 153. Australia Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 154. Australia Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 155. Rest of Asia-Pacific Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 158. Europe Point of Care Molecular Diagnosis, by Country USD Million (2025-2030)
  • Table 159. Europe Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 160. Europe Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 161. Europe Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 162. Germany Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 163. Germany Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 164. Germany Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 165. France Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 166. France Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 167. France Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 168. Italy Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 169. Italy Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 170. Italy Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 171. United Kingdom Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 172. United Kingdom Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 173. United Kingdom Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 174. Netherlands Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 175. Netherlands Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 176. Netherlands Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 177. Rest of Europe Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 178. Rest of Europe Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 179. Rest of Europe Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 180. MEA Point of Care Molecular Diagnosis, by Country USD Million (2025-2030)
  • Table 181. MEA Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 182. MEA Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 183. MEA Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 184. Middle East Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 185. Middle East Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 186. Middle East Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 187. Africa Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 188. Africa Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 189. Africa Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 190. North America Point of Care Molecular Diagnosis, by Country USD Million (2025-2030)
  • Table 191. North America Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 192. North America Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 193. North America Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 194. United States Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 195. United States Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 196. United States Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 197. Canada Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 198. Canada Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 199. Canada Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 200. Mexico Point of Care Molecular Diagnosis, by End Use USD Million (2025-2030)
  • Table 201. Mexico Point of Care Molecular Diagnosis, by Product USD Million (2025-2030)
  • Table 202. Mexico Point of Care Molecular Diagnosis, by Tests USD Million (2025-2030)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Point of Care Molecular Diagnosis: by End Use USD Million (2018-2023)
  • Figure 5. Global Point of Care Molecular Diagnosis: by Product USD Million (2018-2023)
  • Figure 6. Global Point of Care Molecular Diagnosis: by Tests USD Million (2018-2023)
  • Figure 7. South America Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 8. Asia Pacific Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 9. Europe Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 10. MEA Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 11. North America Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 12. Global Point of Care Molecular Diagnosis share by Players 2023 (%)
  • Figure 13. Global Point of Care Molecular Diagnosis share by Players (Top 3) 2023(%)
  • Figure 14. Global Point of Care Molecular Diagnosis share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Roche (Switzerland) Revenue: by Geography 2023
  • Figure 18. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 20. Biomerieux (France) Revenue, Net Income and Gross profit
  • Figure 21. Biomerieux (France) Revenue: by Geography 2023
  • Figure 22. Danaher (United States) Revenue, Net Income and Gross profit
  • Figure 23. Danaher (United States) Revenue: by Geography 2023
  • Figure 24. Roche diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Roche diagnostics (Switzerland) Revenue: by Geography 2023
  • Figure 26. Meridian biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 27. Meridian biosciences (United States) Revenue: by Geography 2023
  • Figure 28. Quidel (United States) Revenue, Net Income and Gross profit
  • Figure 29. Quidel (United States) Revenue: by Geography 2023
  • Figure 30. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 31. Sanofi (France) Revenue: by Geography 2023
  • Figure 32. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 33. Merck (United States) Revenue: by Geography 2023
  • Figure 34. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 35. Johnson and Johnson (United States) Revenue: by Geography 2023
  • Figure 36. Global Point of Care Molecular Diagnosis: by End Use USD Million (2025-2030)
  • Figure 37. Global Point of Care Molecular Diagnosis: by Product USD Million (2025-2030)
  • Figure 38. Global Point of Care Molecular Diagnosis: by Tests USD Million (2025-2030)
  • Figure 39. South America Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 40. Asia Pacific Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 41. Europe Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 42. MEA Point of Care Molecular Diagnosis Share (%), by Country
  • Figure 43. North America Point of Care Molecular Diagnosis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Roche (Switzerland)
  • Abbott Laboratories (United States)
  • Biomerieux (France)
  • Danaher (United States)
  • Roche diagnostics (Switzerland)
  • Meridian biosciences (United States)
  • Quidel (United States)
  • Sanofi (France)
  • Merck (United States)
  • Johnson and Johnson (United States)
Additional players considered in the study are as follows:
Cardea (United States) , Inflammatix (United States) , Sherlock Biosciences (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 160 Pages 62 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Point of Care Molecular Diagnosis Market Quantitative research analysis
Global Point of Care Molecular Diagnosis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Roche (Switzerland), Abbott Laboratories (United States), Biomerieux (France), Danaher (United States), Roche diagnostics (Switzerland), Meridian biosciences (United States), Quidel (United States), Sanofi (France), Merck (United States) and Johnson and Johnson (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"The Rise in CLIA-Waived Molecular POC Tests" is seen as one of major influencing trends for Point of Care Molecular Diagnosis Market during projected period 2023-2030.
The Point of Care Molecular Diagnosis market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Point of Care Molecular Diagnosis Market Report?

Have a Query? Click Here

Other Related Reports

Bandage Contact Lenses Comprehensive Study by Type (Soft Lens, Rigid Lens, Hybrid Lens, Others), End Users (Hospital, Specialized Clinics, Diagnostic Centres), Treatment (Corneal Injury, Post-Ocular ...
$ 3650
Pressure Ulcer Diagnostics Comprehensive Study by Type (Stage 1, Stage 2, Stage 3, Stage 4), Application (Heels, Elbow, Hips, Base of the Spine), End Users (Hospitals, Specialty Clinics, Diagnostic C...
$ 3650
Medication Packaging Systems Comprehensive Study by Type (Blister Card, Pouch, Others), End-Use Verticals (Retail, Long-term care facility, Hospital, Mail-order Pharmacies, Others), Material (Plastic...
$ 3450
Molecular Transport Medium Comprehensive Study by Type (Viral Transport Medium, Virus Swabs), Indication (Mumps Virus, Influenza, Rhinovirus, Adenovirus, COVID-19, Other), End User (Diagnostic Labora...
$ 3450
Home Care - Comprehensive Study by Indication (Cardiovascular Disorders & Hypertension, Respiratory Diseases, Diabetes, Cancer, Wound Care, Pregnancy, Mobility Disorders, Other), Connectivity (CRM, T...
$ 3750
Chikungunya Rapid Testing Comprehensive Study by Technique (Serological testing techniques, Molecular testing techniques), End User (Hospitals, Academic Institutes, Diagnostic Centres, Research Insti...
$ 3350